Eighty-six ( atazanavir/ritonavir , n = 45 ; darunavir/ritonavir , n = 41 ) patients were included : age 36 ( 31-41 ) years ; 89 % men ; CD4 319 ( 183-425 ) cells/mm ( 3 ) ; and Framingham score 1 % ( 0 % -2 % ) .